Core Insights - The SB221 study demonstrated positive safety results for SON-1010 in combination with atezolizumab for patients with platinum-resistant ovarian cancer (PROC), allowing the study to advance to the expansion phase [1][5][6] - The maximum tolerated dose (MTD) of SON-1010 was established at 1200 ng/kg, with no dose-limiting toxicity or cytokine release syndrome observed [1][2][3] - A partial response (PR) was noted in one patient, with a 44% decrease in tumor size and a significant reduction in the CA 125 biomarker [1][3][5] Study Design and Results - The SB221 study aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SON-1010 combined with atezolizumab, with a focus on establishing the MTD [2][8] - A total of 19 subjects were treated during the dose escalation phase, with one patient achieving a PR at the highest dose [2] - Common adverse effects included fatigue, fevers, and gastrointestinal symptoms, with only one serious adverse event (Grade 2 pneumonitis) reported [3][5] Clinical Implications - The results indicate that SON-1010 may be particularly effective in treating immunologically 'cold' tumors, such as ovarian cancer, by enhancing the immune response [4][7] - The study's findings suggest a potential synergistic effect when SON-1010 is used in combination with immune checkpoint inhibitors [5][6] - The safety profile observed in this trial is promising, especially given the historical safety concerns associated with rhIL-12 therapies [5][6] Future Directions - The SB221 trial will proceed to a Phase 2a randomized comparison with standard care for PROC patients [1][8] - Sonnet BioTherapeutics is seeking partnership opportunities to support the later stages of SON-1010's development [6][11]
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose